[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:multiple-sclerosis:x-linked-lymphoproliferative-syndrome-1":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Multiple Sclerosis","X-linked Lymphoproliferative Syndrome 1",3,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06138132","A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis",[12],"Phase 1","RECRUITING","2026-08-26T02:16:29.226604Z","2026-05-05T02:43:27.264594Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06735248","A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years",[20],"Phase 2","2026-08-26T02:19:14.560989Z","2026-05-05T02:35:31.876029Z",{"nct_id":24,"title":25,"phases":26,"status":27,"updated_at":28,"content_modified":29},"NCT05957913","Effects of Antiviral Therapies on Epstein-Barr Virus Replication",[20],"ENROLLING_BY_INVITATION","2026-08-26T02:16:47.762107Z","2026-06-16T05:54:08.092801Z"]